2018 NDAs: Living In The Wake Of 2017

By ISR

With 46 new drugs approved in 2017 (51 if you include five biosimilars), we see that the pharma industry was quite busy. The number of new drug approvals more than doubled from 2016’s level of 22, which begs the question: What is the knock-on effect of a near-record volume of approvals? When one thinks about the potential impact on manufacturing, market access, late-phase clinical development, and sales and marketing activities, the impact is likely substantial.